<SEC-DOCUMENT>0001193125-21-274001.txt : 20210915
<SEC-HEADER>0001193125-21-274001.hdr.sgml : 20210915
<ACCEPTANCE-DATETIME>20210915163057
ACCESSION NUMBER:		0001193125-21-274001
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210915
FILED AS OF DATE:		20210915
DATE AS OF CHANGE:		20210915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Autolus Therapeutics plc
		CENTRAL INDEX KEY:			0001730463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38547
		FILM NUMBER:		211255687

	BUSINESS ADDRESS:	
		STREET 1:		THE MEDIAWORKS
		STREET 2:		191 WOOD LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W12 7FP
		BUSINESS PHONE:		44 20 3829 6230

	MAIL ADDRESS:	
		STREET 1:		THE MEDIAWORKS
		STREET 2:		191 WOOD LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W12 7FP

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Autolus Therapeutics Ltd
		DATE OF NAME CHANGE:	20180205
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d210400d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of September 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-38547</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Autolus Therapeutics plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The
MediaWorks </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>191 Wood Lane </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London W12 7FP </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>United
Kingdom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Forest House </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>58 Wood
Lane </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>White City </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London W12 7RZ </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>United
Kingdom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former address) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#9746;&nbsp;&nbsp;Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> (the &#147;Report&#148;) and Exhibit 99.1 to this Report shall be deemed to be incorporated by
reference into the registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-232690),</FONT> Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-258556)</FONT> and Form <FONT STYLE="white-space:nowrap">S-8</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-226457)</FONT> of Autolus Therapeutics plc (including any prospectuses forming a
part of such registration statements) and to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appointment of New Director </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;15, 2021,
Autolus Therapeutics plc (the &#147;Company&#148;) announced that, upon the recommendation of its Nominating and Corporate Governance Committee (the &#147;Nominating Committee&#148;) of the Company&#146;s Board of Directors (the &#147;Board&#148;),
the Board appointed John H. Johnson to serve as a Class&nbsp;II director of the Company and as chair of the Board, effective September&nbsp;15, 2021. Mr.&nbsp;Johnson will serve for an initial term expiring at the Company&#146;s 2023 annual meeting
of stockholders, and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the
appointment of Mr.&nbsp;Johnson as director and as an independent chair, Dr.&nbsp;Martin Murphy will resign as the current chair of the Board, and Mr.&nbsp;John Berriman will resign as lead independent director of the Board, each effective
September&nbsp;15, 2021. Dr.&nbsp;Murphy and Mr.&nbsp;Berriman will continue to serve as directors of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Johnson will be compensated in
accordance with the terms of the Company&#146;s <FONT STYLE="white-space:nowrap">non-executive</FONT> director compensation policy, which has been amended in September 2021 to reflect an updated annual retainer for a
<FONT STYLE="white-space:nowrap">non-executive</FONT> chair and an updated initial equity award for a <FONT STYLE="white-space:nowrap">non-executive</FONT> chair. Pursuant to the policy amended as of September 2021, Mr.&nbsp;Johnson will be entitled
to receive a &pound;50,000 annual retainer for his service as <FONT STYLE="white-space:nowrap">non-executive</FONT> chair of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, pursuant
to the policy amended as of September 2021, in connection with Mr.&nbsp;Johnson&#146;s appointment as non-executive chair of the Board, he will also be granted an initial, <FONT STYLE="white-space:nowrap">one-time</FONT> equity award of options to
purchase 50,000 of the Company&#146;s American Depositary Shares (&#147;ADSs&#148;) representing its ordinary shares, with an exercise price equal to the closing price of the Company&#146;s ADSs on September&nbsp;15, 2021, the date of his
appointment. The initial option award to the chairperson has been increased compared to the initial equity award granted to other new non-executive directors, for whom the initial option award remains at 25,000 of the Company&#146;s ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The award will vest and become exercisable in equal monthly installments through the third anniversary of Mr.&nbsp;Johnson&#146;s date of appointment to the
Board, subject to his continued service to the Company through each applicable vesting date. The Company also entered into its standard deed of indemnity agreement for directors and officers with Mr.&nbsp;Johnson, the form of which was filed as an
exhibit to the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> 224720) filed with the SEC on June&nbsp;8, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between Mr.&nbsp;Johnson and any other persons pursuant to which Mr.&nbsp;Johnson was appointed as a director, and
there are no related-party transactions in which Mr.&nbsp;Johnson has an interest requiring disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;15, 2021, the Company issued a
press release announcing the aforementioned changes to the Board which is furnished as Exhibit 99.1 to this Report. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d210400dex991.htm">Press release dated September&nbsp;15, 2021. </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"><B>Autolus Therapeutics plc</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;15, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christian Itin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Christian Itin, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d210400dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210400dsp2logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Autolus Therapeutics announces the appointment of John H. Johnson as
<FONT STYLE="white-space:nowrap">non-executive</FONT> chairman of its Board of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LONDON</B>,&nbsp;September 15, 2021 &#151;&nbsp;Autolus
Therapeutics plc&nbsp;(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as <FONT STYLE="white-space:nowrap">non-executive</FONT>
chairman of its Board of Directors, effective September&nbsp;15, 2021. Dr.&nbsp;Martin Murphy, who previously served as chairman, will continue to serve as a <FONT STYLE="white-space:nowrap">non-executive</FONT> Board member.<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Johnson brings to Autolus more than 30 years of experience in the life science industry. He is currently chief executive officer and a director of
Strongbridge Biopharma plc, a NASDAQ listed commercial stage biopharmaceutical company. He previously served as the executive chairman of the company from November 2019 to July 2020, and as chairman from March 2015 to November 2019. He is a
recognized leader in the biopharmaceutical industry and has held executive, operations and commercial leadership roles at Eli Lilly&nbsp;&amp; Company, ImClone, Johnson&nbsp;&amp; Johnson, and Pfizer. He also currently serves as a member of the
Board of Directors of Verastem, Inc and Axogen, Inc. Mr.&nbsp;Johnson previously served on the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry
Organizations (BIO), BioNJ and holds a BS from the East Stroudsburg University of Pennsylvania. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are entering an exciting time in Autolus&#146;
evolution as we progress <FONT STYLE="white-space:nowrap">obe-cel</FONT> towards pivotal data and the expectation that <FONT STYLE="white-space:nowrap">obe-cel</FONT> could become the first stand-alone therapy with curative potential for adult acute
lymphoblastic leukemia (ALL) patients,&#148; said Dr.&nbsp;Christian Itin, chief executive officer of Autolus. &#147;Together with the entire board and management team I am delighted to welcome John as chairman of our Board. John&#146;s experience
in leading oncology-focused commercial-stage biopharmaceutical businesses will be invaluable as we start preparing for a successful outcome of the ongoing pivotal FELIX study of <FONT STYLE="white-space:nowrap">obe-cel.&#148;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am delighted to serve as chairman of Autolus at such an important time in the Company&#146;s development,&#148; said John H. Johnson. &#147;I am
confident in Autolus&#146; ability to deliver its first pivotal data for its lead program in 2022 and am excited to work closely with the Board and Autolus&#146; experienced senior management team to develop therapies that may offer cancer patients
substantial benefits over existing standards of care.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Autolus Therapeutics plc </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite
of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and
eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit <U>www.autolus.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">Obe-cel</FONT></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Obe-cel</FONT> is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.&nbsp;Designed to have a fast target binding <FONT
STYLE="white-space:nowrap">off-rate</FONT> to minimize excessive activation of the programmed T cells, <FONT STYLE="white-space:nowrap">Obe-cel</FONT> may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and
improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with our academic partner, UCL, <FONT STYLE="white-space:nowrap">Obe-cel</FONT> is currently being evaluated in a Phase 1 clinical
trial in adult ALL and <FONT STYLE="white-space:nowrap">B-NHL.</FONT> The company has also progressed <FONT STYLE="white-space:nowrap">Obe-cel</FONT> to the FELIX study, a potential pivotal study. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">Obe-cel</FONT> FELIX study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FELIX Phase 1b/2 clinical trial is enrolling adult patients with relapsed / refractory ALL. The trial has a short Phase 1b component prior to proceeding to
a single arm Phase 2 clinical trial. The primary endpoint is overall response rate, and the key secondary endpoints include duration of response, MRD negative CR rate and safety. The trial will enroll approximately 100 patients across 30 of the
leading academic and <FONT STYLE="white-space:nowrap">non-academic</FONT> centers in the United States,&nbsp;United Kingdom&nbsp;and&nbsp;Europe. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be
identified by terms such as &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; and &#147;believes.&#148; These statements include, but are not limited to, statements regarding the
future clinical development, efficacy, safety and therapeutic potential of <FONT STYLE="white-space:nowrap">obe-cel,</FONT> including progress, expectations as to the reporting of data, conduct and timing and potential future clinical activity and
milestones; expectations regarding the initiation, design and reporting of data from clinical trials. Any forward-looking statements are based on management&#146;s current views and assumptions and involve risks and uncertainties that could cause
actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus&#146; preclinical or clinical programs do not
advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product
candidates do not become approved drugs on a timely or cost effective basis or at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on
Autolus&#146; business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus&#146; actual results to differ from those contained in the forward-looking statements, see the section titled
&#147;Risk Factors&#148; in Autolus&#146; Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> filed with the Securities and Exchange Commission on March&nbsp;4, 2021, as well as discussions of potential risks, uncertainties, and other
important factors in Autolus&#146; subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise, except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lucinda Crabtree, PhD </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Business Strategy and
Planning </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+44 (0)&nbsp;7587 372 619</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>l.crabtree@autolus.com
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Julia Wilson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+44 (0) 7818 430877 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>j.wilson@autolus.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Susan A. Noonan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S.A. Noonan Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-212-966-3650</FONT></FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>susan@sanoonan.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g210400dsp2logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210400dsp2logo.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MFW-MH]H^#OB>/6_"2:=(^;S3 (G!ZE.=A_(8_"N.O#DD=-*7-$]%K V"@ H
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MN_BK?7NAPR1:1$LC8?C:C?=7ZY[>U;U]*:4MS&EK)M;'T%7$=AF:]H&G>([
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MA**3NC1U+2[+6+"6QU"W2XMI1AXW'!_^O[TDW%W0-)[G$0?!;PC#>B=H+B5
M<B%YB4^A[D5JZ\[6,U1C>YT%SX%\.75[87DFFH); !;?RV*+& =P  ('6H52
M231?*KZ&IJVC:=KEBUEJ=I'=6[')209Y]1W!]Q4Q;B[HIQNK'#O\$O"#3^8L
M=VB?\\UG./\ &MOK$^YE[&)V>B>'M+\.6 LM*M$MX,[B!DECZDGDFLI2<W[Q
MHHI*R-2I* T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
# ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
